Craniosynostosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Recently, the single-cell metric termed polyfunctional strength index (PSI™) by IsoCode chip computed from preinfusion anti-CD19 chimeric antigen receptor (CAR)-T cell products has demonstrated a significant association with clinical response and cytokine release syndrome (CRS) of cancer patient to the therapy after cell product infusion.
|
31502163 |
2020 |
Craniosynostosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this review we describe CRS and neurotoxicity in patients with B cell malignancies treated with CD19 CAR-T cells in pivotal trials, and also provide insight into potential mechanisms associated with these toxicities based on studies conducted in a phase 1/2 clinical trial at the Fred Hutchinson Cancer Research Center.
|
31431714 |
2019 |
Craniosynostosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Chimeric antigen receptor (CAR)-modified T cells targeting CD19 demonstrate unparalleled responses in relapsed/refractory acute lymphoblastic leukemia (ALL)<sup>1-5</sup>, but toxicity, including cytokine-release syndrome (CRS) and neurotoxicity, limits broader application.
|
31477906 |
2019 |
Craniosynostosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
These data support the contention that early intervention with tocilizumab and/or corticosteroids in subjects with early signs of CRS is without negative impact on the antitumor potency of CD19 CAR T cells.
|
31697826 |
2019 |
Craniosynostosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
CD19-targeting chimeric antigen receptor (CAR)-T cell therapy has shown great efficacy in patients with relapsed/refractory non-Hodgkin lymphoma (NHL) but has been associated with serious adverse effects, such as cytokine release syndrome (CRS).
|
30769193 |
2019 |
Craniosynostosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Although the IL-6R antagonist tocilizumab is approved for treatment of CRS, there is no approved treatment of neurotoxicity associated with CD19-targeted CAR-T (CART19) cell therapy.
|
30463995 |
2019 |
Craniosynostosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Although CART19-induced complications have been gradually recognized, local cytokine-release syndrome (CRS) at particular parts of the body has not been extensively studied.
|
30563981 |
2019 |
Craniosynostosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Thus, therapy with the new CD19-BBz(86) CAR T cells produces a potent and durable antilymphoma response without causing neurotoxicity or severe CRS, representing a safe and potent anti-CD19 CAR T cell therapy.
|
31011207 |
2019 |
Craniosynostosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Blinatumomab, a monoclonal antibody targeting CD19, is associated with cytokine release syndrome (CRS) and neurotoxicity, both of which require prompt recognition and management primarily with corticosteroids.
|
30482769 |
2018 |
Craniosynostosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Blinatumomab, a monoclonal antibody targeting CD19, is associated with cytokine release syndrome (CRS) and neurotoxicity, both of which require prompt recognition and management primarily with corticosteroids.
|
30504288 |
2018 |
Craniosynostosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Although cytokine release syndrome (CRS) and neurotoxicity have emerged as predominant noninfectious complications of CD19 CAR T-cell therapy, infections associated with this treatment modality have not been well documented.
|
29481659 |
2018 |
Craniosynostosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Clinical experience with the anti-CD19 CAR T cell therapy tisagenlecleucel at the University of Pennsylvania (Penn) was used to develop the Penn grading scale for CRS.
|
29499750 |
2018 |
Craniosynostosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In this report of our presentation at the 2018 Second French International Symposium on CAR-T cells (CAR-T day), we describe the clinical presentations of CRS and neurotoxicity in a cohort of 133 adults treated with CD19 CAR-T cells at the Fred Hutchinson Cancer Research Center, and provide insights into the mechanisms contributing to these toxicities.
|
29625831 |
2018 |
Craniosynostosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Besides, post-HSCT CD19 CAR-T cell infusion represented lower severe CRS incidence.
|
29766234 |
2018 |
Craniosynostosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
We report the clinical presentation of and identify biomarkers of severe CRS in 133 adult patients who received CD19 CAR T cells.
|
28924019 |
2017 |
Craniosynostosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
We have demonstrated, in a humanized mouse model, that the inducible caspase-9 (iC9) safety switch can eliminate CD19.CAR-Ts in a dose-dependent manner, allowing either a selective containment of CD19.CAR-T expansion in case of CRS or complete deletion on demand granting normal B cell reconstitution.
|
28187946 |
2017 |
Craniosynostosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Chimeric antigen receptor (CAR) T-cell therapy targeting CD19 has demonstrated remarkable success in targeting B-cell malignancies but is often complicated by serious systemic toxicity in the form of cytokine release syndrome (CRS).
|
28506444 |
2017 |
Craniosynostosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Trials with second generation CD19 chimeric antigen receptors (CAR) T-cells report unprecedented responses but are associated with risk of cytokine release syndrome (CRS).
|
28126984 |
2017 |